Clinical Implications—In the case of metastatic CRC, the higher frequency of KRAS mutations among these tumors reduces standard chemotherapeutic options, as mutant KRAS is usually an indicator of poor response to epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs, e.g., cetuximab) [55,56]. This evidence concerns the gene EGFR and colorectal carcinoma.